Android app Apple app link

Telix Pharma doses first patient in Phase III PET carcinoma trial

By Yahoo! Finance   |   4 weeks ago
Telix Pharma doses first patient in Phase III PET carcinoma trial

Telix Pharmaceuticals has initiated its Phase III ZIRCON-CP trial for TLX250-CDx, a PET imaging agent for renal cell carcinomas. The study, in collaboration with Grand Pharmaceutical Group, aims to further validate the effectiveness of the method in Chinese populations.

Read More

Did you find this insightful?

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.